More than 15 FDA-approved treatments have originated from discoveries made in Scripps Research labs. These have impacted the health of millions of people around the world—from a drug that helps premature infants breathe to vaccines for COVID-19.


ABthraxTM

raxibacumab

A monoclonal antibody engineered to destroy the anthrax toxin, purchased
by the U.S. government to protect against potential bioterror attack. 


COVID-19 vaccines

Developed in record time using key innovations from Scripps Research, these vaccines help protect people from SARS-CoV-2, the coronavirus that causes COVID-19


Zeposia®

ozanimod

A once-daily oral medicine for patients with relapsing forms of multiple sclerosis.


Trodelvy®

sacituzumab govitecan-hziy

Scientists used “click chemistry” to create this novel treatment for bladder cancer, urinary tract cancers and triple-negative breast cancer.


Vyndaqel®

tafamidis meglumine

Vyndamax®

tafamidis

Both medicines treat a debilitating, often fatal heart disease caused by protein buildup.


Mavenclad®

cladribine, oral

The first short-course oral medicine for patients with relapsing forms of multiple sclerosis.


Takhzyro®

lenadelumab-flo

Helps prevent attacks of hereditary angioedema, a rare disorder that disrupts the normal flow of blood and other fluids in the body.


Palynziq®

pegvaliase-pqpz

A novel enzyme therapy for adults with phenylketonuria (PKU), a rare and serious
genetic disease. 


Bavencio®

avelumab

The first treatment for patients with metastatic Merkel cell carcinoma, now used to confront other carcinomas as well.


Unituxin®

dinutuximab

In combination with chemotherapy, treats pediatric patients with neuroblastoma, a rare brain cancer.


Portrazza®

necitumumab

Treats metastatic squamous non-small cell lung cancer, used in combination with existing chemotherapies.


Cyramza®

ramucirumab

Treats advanced gastric cancer, liver cancer and metastatic, non-small cell lung cancer.


Surfaxin®

lucinactant

Prevents respiratory distress syndrome in premature infants and injured adults.


Benlysta®

belimumab

Debuted in 2011 as the first new lupus therapy in 50 years.


Humira®

adalimumab

Prescribed worldwide to treat arthritis and other autoimmune conditions.


Leustatin®

cladribine, IV

Cures or offers a lifetime of remission for patients with hairy cell leukemia.